Basel, Switzerland

Sandoz

Swiss generic and biosimilar medicines company. In GLP-1s it has a marketing authorisation for a generic semaglutide (a version of Ozempic) in Canada, holds commercial rights to a semaglutide product approved in Brazil that was developed by Adalvo, and has US FDA applications under review for an in-house generic tirzepatide. Its tirzepatide applications are under FDA review and are not approved. Details below are as Sandoz states them in its own media releases.

Canada: generic semaglutide (September 2026)

On 18 September 2026 Sandoz announced that Health Canada had granted marketing authorisation for Sandoz Semaglutide, a generic version of Ozempic, for once-weekly use in adults with type 2 diabetes. Sandoz described the Canadian GLP-1 market as worth USD 2.6 billion and said it foresaw no material contribution in 2026 from any potential launches of generic semaglutide.[src]

Brazil: Owozy (July 2026)

On 29 July 2026 Sandoz announced that Brazil's health regulator ANVISA had granted marketing authorisation for Owozy (semaglutide) for type 2 diabetes. Owozy was developed by Adalvo, and Sandoz will commercialise it in Brazil in partnership with Adalvo, with a launch expected in the second half of 2026. Sandoz said it foresaw no material contribution in 2026 from any potential launch of generic semaglutide.[src]

US: generic tirzepatide applications (June 2026)

On 29 June 2026 Sandoz announced that the US FDA had accepted for review two Abbreviated New Drug Applications for an in-house generic tirzepatide autoinjector, referencing Mounjaro and Zepbound. Acceptance for review is not an approval; Sandoz said any launch is subject to FDA approval.[src]

Company scale

In the same June 2026 release Sandoz states that it recorded net sales of USD 11.1 billion in 2025 and that its global portfolio comprises 1,300 generic medicines.[src]